biostudies-literatureMartin-Broto JCelgene6278https://www.ebi.ac.uk/biostudies/studies/S-EPMC9587294biostudies-literatureUnknown13(1)Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best rNature communicationsA phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.PMC9587294AX-CL-GEIS-007345Valverde CRedondo AMarcilla DMoura DSMartinez-Trufero JLopez-Martin JAGutierrez ALedesma PHindi NMartinez-Marin VMorales JMDi Lernia DLopez-Pousa ADiaz-Beveridge RZamora JMartin-Broto JLuna PArribas IfalseA phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best r2022-01-01T00:00:00Z2022 Oct2026-05-27T23:06:40.39Z2025-02-18T23:29:39.374ZS-EPMC95872943627101110.1038/s41467-022-33975-6